BIO “Follow-On” Biologics Risk-Based Proposal Would Require Clinical Tests
Executive Summary
The Biotechnology Industry Organization's risk-based approach to a regulatory pathway for "follow-on" biologics would include a clinical testing requirement
You may also be interested in...
GPhA Offers Risk-Based Approach To “Follow-On” Biologics Immunogenicity
Pre-approval testing for "follow-on" biologics should focus on determining product factors with the greatest risk of immunogenicity, the Generic Pharmaceutical Association said
FDA Follow-On Biologics Background Document To Be Released By Year-End
FDA is developing a background document as part of its ongoing action on "follow-on" biologics, Acting Commissioner for Operations Janet Woodcock, MD, said
Flu Vaccine Shortage Shows Hazards Of Market Concentration – Sen. Leahy
The Bush Administration should have "learned their lesson" from last year's influenza vaccine shortages, Sen. Patrick Leahy (D-Vt.) says